Patents Assigned to Orphalan S.A.
  • CRYSTALLINE FORM OF TRIETHYLENETETRAMINE TETRAHYDROCHLORIDE AND ITS PHARMACEUTICAL USE
    Publication number: 20220169594
    Abstract: The present invention describes a new crystalline form of triethylenetetramine tetrachloride which has improved room temperature stability over known forms and over the dichloride salt. The new crystalline form is characterised by having peaks in an XRPD spectrum at 22.9, 25.4, 25.8, 26.6, 34.6 and 35.3±0.1° 2? and Raman shifts 943, 1173, 1527 and 1612±5 cm?1. The crystalline form of triethylenetetramine tetrachloride is useful in the treatment of Wilson's disease.
    Type: Application
    Filed: August 10, 2021
    Publication date: June 2, 2022
    Applicant: Orphalan S.A.
    Inventors: Timothy James Morley, Ronnie Maxwell Lawrence, Naseem Amin
  • Crystalline form of triethylenetetramine tetrahydrochloride and its pharmaceutical use
    Patent number: 11117855
    Abstract: The present invention describes a new crystalline form of triethylenetetramine tetrachloride which has improved room temperature stability over known forms and over the dichloride salt. The new crystalline form is characterised by having peaks in an XRPD spectrum at 22.9, 25.4, 25.8, 26.6, 34.6 and 35.3±0.1°2? and Raman shifts 943, 1173, 1527 and 1612±5 cm?1. The crystalline form of triethylenetetramine tetrachloride is useful in the treatment of Wilson's disease.
    Type: Grant
    Filed: February 9, 2021
    Date of Patent: September 14, 2021
    Assignee: Orphalan S.A.
    Inventors: Timothy James Morley, Ronnie Maxwell Lawrence, Naseem Amin
  • Crystalline form of triethylenetetramine tetrahydrochloride and its pharmaceutical use
    Patent number: 11072577
    Abstract: The present invention describes a new crystalline form of triethylenetetramine tetrachloride which has improved room temperature stability over known forms and over the dichloride salt. The new crystalline form is characterised by having peaks in an XRPD spectrum at 22.9, 25.4, 25.8, 26.6, 34.6 and 35.3±0.1°2? and Raman shifts 943, 1173, 1527 and 1612±5 cm?1. The crystalline form of triethylenetetramine tetrachloride is useful in the treatment of Wilson's disease.
    Type: Grant
    Filed: February 9, 2021
    Date of Patent: July 27, 2021
    Assignee: Orphalan S.A.
    Inventors: Timothy James Morley, Ronnie Maxwell Lawrence, Naseem Amin
  • CRYSTALLINE FORM OF TRIETHYLENETETRAMINE TETRAHYDROCHLORIDE AND ITS PHARMACEUTICAL USE
    Publication number: 20210188761
    Abstract: The present invention describes a new crystalline form of triethylenetetramine tetrachloride which has improved room temperature stability over known forms and over the dichloride salt. The new crystalline form is characterised by having peaks in an XRPD spectrum at 22.9, 25.4, 25.8, 26.6, 34.6 and 35.3±0.1°2? and Raman shifts 943, 1173, 1527 and 1612±5 cm?1. The crystalline form of triethylenetetramine tetrachloride is useful in the treatment of Wilson's disease.
    Type: Application
    Filed: February 9, 2021
    Publication date: June 24, 2021
    Applicant: Orphalan S.A.
    Inventors: Timothy James Morley, Ronnie Maxwell Lawrence, Naseem Amin
  • CRYSTALLINE FORM OF TRIETHYLENETETRAMINE TETRAHYDROCHLORIDE AND ITS PHARMACEUTICAL USE
    Publication number: 20210163398
    Abstract: The present invention describes a new crystalline form of triethylenetetramine tetrachloride which has improved room temperature stability over known forms and over the dichloride salt. The new crystalline form is characterised by having peaks in an XRPD spectrum at 22.9, 25.4, 25.8, 26.6, 34.6 and 35.3±0.1°2? and Raman shifts 943, 1173, 1527 and 1612±5 cm?1. The crystalline form of triethylenetetramine tetrachloride is useful in the treatment of Wilson's disease.
    Type: Application
    Filed: February 9, 2021
    Publication date: June 3, 2021
    Applicant: Orphalan S.A.
    Inventors: Timothy James Morley, Ronnie Maxwell Lawrence, Naseem Amin
  • Crystalline form of triethylenetetramine tetrahydrochloride and its pharmaceutical use
    Patent number: 10988436
    Abstract: The present invention describes a new crystalline form of triethylenetetramine tetrachloride which has improved room temperature stability over known forms and over the dichloride salt. The new crystalline form is characterised by having peaks in an XRPD spectrum at 22.9, 25.4, 25.8, 26.6, 34.6 and 35.3±0.1°2? and Raman shifts 943, 1173, 1527 and 1612±5 cm?1. The crystalline form of triethylenetetramine tetrachloride is useful in the treatment of Wilson's disease.
    Type: Grant
    Filed: June 30, 2020
    Date of Patent: April 27, 2021
    Assignee: Orphalan S.A.
    Inventors: Timothy James Morley, Ronnie Maxwell Lawrence, Naseem Amin
  • Crystalline form of triethylenetetramine tetrahydrochloride and its pharmaceutical use
    Patent number: 10947184
    Abstract: The present invention describes a new crystalline form of triethylenetetramine tetrachloride which has improved room temperature stability over known forms and over the dichloride salt. The new crystalline form is characterised by having peaks in an XRPD spectrum at 22.9, 25.4, 25.8, 26.6, 34.6 and 35.3±0.1°2? and Raman shifts 943, 1173, 1527 and 1612±5 cm?1. The crystalline form of triethylenetetramine tetrachloride is useful in the treatment of Wilson's disease.
    Type: Grant
    Filed: June 30, 2020
    Date of Patent: March 16, 2021
    Assignee: Orphalan S.A.
    Inventors: Timothy James Morley, Ronnie Maxwell Lawrence, Naseem Amin